Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition
The therapeutic benefits of immune checkpoint inhibitors (ICIs), which enable antitumor immune responses, can be tempered by unwanted immune-related adverse events (irAEs). Treatment recommendations stratified by irAE phenotype and immunohistopathological findings have only recently been proposed an...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Revisão |
| Kieli: | englanti |
| Julkaistu: |
2022
|
| Linkit: | https://doi.org/10.1136/jitc-2021-003551 https://jitc.bmj.com/content/jitc/10/1/e003551.full.pdf |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|